文献速递妇科生殖医学

45岁以下子宫内膜癌保守治疗更新

Updates on conservative management of endometrial cancer in patients younger than 45 years.
PubMed 文献 · Gynecol Oncol · 2021-04-20

该系统综述纳入38项研究共661例45岁以下1-2级子宫内膜癌患者,比较不同保留生育功能治疗的肿瘤与生育结局。宫腔镜切除后辅以孕激素的完全缓解率90%、进展率3.5%、妊娠率34.5%,均优于单纯激素治疗或左炔诺孕酮宫内装置。

要点

  • 宫腔镜切除联合孕激素完全缓解率90%,进展率仅3.5%。
  • 宫腔镜切除组妊娠率34.5%,高于激素治疗27.6%和左炔诺孕酮装置18.4%。
  • 宫腔镜切除组后续子宫切除人数更少。

核心结论

  • 宫腔镜切除后使用孕激素与更好的完全缓解、更高的妊娠率和更少的子宫切除相关。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE和CINAHL数据库2010年1月至2020年1月文献,纳入38项研究共661例45岁以下1级或2级子宫内膜癌患者。
  • 中位年龄32.3岁(范围13-43)。

主要发现

  • 总体完全缓解率为79.4%,宫腔镜切除组90%、激素治疗组77.7%、左炔诺孕酮宫内装置组71.3%。
  • 宫腔镜切除作为主要治疗时P=0.02,且总是后续口服孕激素或左炔诺孕酮宫内装置。
  • 肿瘤切除患者进展率3.5%,低于激素治疗的12.1%和左炔诺孕酮宫内装置的19.5%(P=0.03)。
  • 宫腔镜切除组完全缓解时间更长(P=0.04),接受子宫切除的患者更少(P=0.0001)。
  • 妊娠率:宫腔镜切除组34.5%、药物治疗组27.6%、左炔诺孕酮宫内装置组18.4%(P=0.002)。

关键数值与推荐

  • 中位随访时间47.92个月(范围1-412),孕激素组54.9个月(范围3.4-412),宫腔镜切除组38.97个月(范围3-172),左炔诺孕酮宫内装置组23.11个月(范围1-115.5)。

临床怎么用

  • 对45岁以下1-2级子宫内膜癌要求保留生育者,可优先考虑宫腔镜切除联合孕激素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endometrial cancer is the most common gynecologic malignancy in developed country. Women under the age of 40 represent 5% of all endometrial cancer and the majority are nulliparous at the time of diagnosis. The aim of this review was to compare oncologic and fertility outcomes among different fertility-preserving therapies in patients under 45 years of age with grade 1 or 2 endometrial cancer. A systematic review was conducted, the MEDLINE, EMBASE, and CINAHL databases were searched for articles published during the period from January 2010 through January 2020 in accordance with PRISMA guidelines, using the terms endometrial cancer, fertility sparing treatment and conservative treatment. A total of 661 patients in 38 studies were included. The median age was 32.3 years (range 13--43). Regardless of the primary treatment, it is always accompanied by systemic or local hormonal treatment. The median follow-up time was 47.92 months (range 1-412), 54.9 months (range 3.4-412) for the progesterone group, 38.97 months (range 3-172) for the hysteroscopic resection group and 23.11 months (range 1-115.5) for the Levonorgestrel Intrauterine Device group. The overall complete response rate was 79.4%, [Hysteroscopic Resection: 90%, hormonal treatment: 77.7%, and Levonorgestrel Intrauterine Device: 71.3%] The p = 0.02 when the primary treatment is Hysteroscopic resection, always followed by hormonal therapy either oral progesterone or Levonorgestrel Intrauterine Device. Patients who had tumor resection had lower progression than those who received hormonal treatment or Levonorgestrel Intrauterine Device 3.5% vs. 12.1% vs. 19.5% respectively (p = 0.03). The complete response time was higher in the Hysteroscopic Resection group (p = 0.04) with fewer patients undergoing hysterectomy (p = 0.0001). Patients who underwent Hysteroscopic Resection had higher pregnancy rates compared to medical treatment or Levonorgestrel Intrauterine Device, 34.5%, 27.6% and 18.4%, respectively (p = 0.002). CONCLUSION: Patients who underwent Hysteroscopic Resection followed progestogens agent was associated to a better complete response, high pregnancy rates and minor numbers of hysterectomies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lucchini SM, Esteban A, Nigra MA, et al. Updates on conservative management of endometrial cancer in patients younger than 45 years. Gynecol Oncol. 2021. PMID: 33892887. doi:10.1016/j.ygyno.2021.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。